Summarized by Masters of Longevity from Nature - Main.
Reports on the approved orexin agonist and why researchers and companies expect the drug class to expand beyond sleep disorders into broader clinical uses.
Key Takeaways
- Much like blockbuster GLP-1 drugs, such as Ozempic, which were initially approved to treat diabetes but have since taken off as treatments for other conditions, these new drugs seem capable of much more than treating sleep disorders.
- “Anyone who has gotten a poor night of sleep can tell you that it impacts nearly every aspect of their life,” says Luis de Lecea, a psychiatrist at Stanford University in California, who was among the first to identify orexins.
- Groups at the institute were divvying up brain regions to study, and de Lecea chose the hypothalamus, an almond-sized region deep in the brain’s interior.
